Business Wire07.09.21
Lumos Diagnostics has expanded its board with the appointment of three new independent directors to support the continued growth of the company’s rapid point-of-care diagnostic products and services business. Bronwyn Le Grice, Lawrence Mehren, and Catherine Robson will join Executive Chair Sam Lanyon and and Executive Director Rob Sambursky, M.D.
“On behalf of the entire company, I am delighted to welcome Bronwyn, Larry and Catherine to the Lumos Board of Directors,” said Lanyon. “Together, they offer extensive and diverse operational experience in growing diagnostic companies, strong knowledge of equity markets and broad corporate governance expertise. Lumos will benefit from their guidance as we expand our commercial infrastructure and global market access to novel point-of-care tests.”
Le Grice brings expertise in digital health and public market knowledge. She has more than 18 years executive experience in the health technology sector including venture capital, corporate development and industry advocacy. In 2017, Le Grice founded ANDHealth, Australia’s only dedicated digital health accelerator and commercialization support organization.
Mehren provides diagnostic operational proficiency and public market experience. He served as CEO and a director of Accelerate Diagnostics from 2012 to 2020. Before this, Mehren served as senior vice president and chief financial officer of Ventana Medical Systems Inc. from 2007 until 2008 and as head of Global Business from 2008 until 2011.
Robson expands Lumos’ financial capabilities and corporate governance experience. She founded Affinity Private, a financial services firm and has non-executive director experience at Greater Bank, SCALE Investors and on ASX-listed Equity Trust Limited (EQT) Holdings Limited. Robson was previously a member of both the EQT Board Risk Committee and the Board Remuneration, Human Resources and Nominations Committee.
Lanyon has more than 25 years of experience in business strategy, executive sales and operational management with a demonstrated track record in the global commercialization of technology rich healthcare products. He also serves as co-CEO and co-founder of Planet Innovation.
Sambursky is one of the original founders and former executives of RPS Diagnostics, which merged with Lumos Diagnostics in 2019, and currently leads Lumos as its president and CEO. In addition to his product development and commercial experience, he has a strong scientific and clinical background in medical sciences, ophthalmology and infectious disease.
“On behalf of the entire company, I am delighted to welcome Bronwyn, Larry and Catherine to the Lumos Board of Directors,” said Lanyon. “Together, they offer extensive and diverse operational experience in growing diagnostic companies, strong knowledge of equity markets and broad corporate governance expertise. Lumos will benefit from their guidance as we expand our commercial infrastructure and global market access to novel point-of-care tests.”
Le Grice brings expertise in digital health and public market knowledge. She has more than 18 years executive experience in the health technology sector including venture capital, corporate development and industry advocacy. In 2017, Le Grice founded ANDHealth, Australia’s only dedicated digital health accelerator and commercialization support organization.
Mehren provides diagnostic operational proficiency and public market experience. He served as CEO and a director of Accelerate Diagnostics from 2012 to 2020. Before this, Mehren served as senior vice president and chief financial officer of Ventana Medical Systems Inc. from 2007 until 2008 and as head of Global Business from 2008 until 2011.
Robson expands Lumos’ financial capabilities and corporate governance experience. She founded Affinity Private, a financial services firm and has non-executive director experience at Greater Bank, SCALE Investors and on ASX-listed Equity Trust Limited (EQT) Holdings Limited. Robson was previously a member of both the EQT Board Risk Committee and the Board Remuneration, Human Resources and Nominations Committee.
Lanyon has more than 25 years of experience in business strategy, executive sales and operational management with a demonstrated track record in the global commercialization of technology rich healthcare products. He also serves as co-CEO and co-founder of Planet Innovation.
Sambursky is one of the original founders and former executives of RPS Diagnostics, which merged with Lumos Diagnostics in 2019, and currently leads Lumos as its president and CEO. In addition to his product development and commercial experience, he has a strong scientific and clinical background in medical sciences, ophthalmology and infectious disease.
